Lack of alpha 2-antiplasmin enhances ADP induced platelet micro-aggregation through the presence of excess active plasmin in mice.

Abstract:

BACKGROUND:The role of alpha2-antiplasmin (alpha2-AP) on platelet aggregation was investigated using mice deficient in alpha2-AP (alpha2-AP(-/-)) or using wild type mice (alpha2-AP(+/+)). METHODS:Blood samples were taken from each mouse under anesthesia with ether and platelet rich plasma (PRP) was prepared. Platelet aggregation induced by various doses of ADP (0.3-30 microM) was detected using a laser-light scattering (LS) system. Aggregated forms were observed using a scanning electron microscopy (SEM). RESULTS:Dose-dependent platelet aggregation was not different in both types of mice. However, platelet micro-aggregate formation in alpha2-AP(-/-) mice induced by low dose of ADP (1.0 microM) markedly increased compared to the situation in wild type mice. Aggregated form detected by SEM showed supported data from LS analysis. When washed platelets of alpha2-AP(+/+) mice were resuspended in plasma of alpha2-AP(-/-) mice, platelet micro-aggregation was also increased. On the contrary, when washed platelets of alpha2-AP(-/-) mice were suspended in plasma of alpha2-AP(+/+) mice, platelet micro-aggregation did not change. In separate experiments, tPA (1.0 microg/ml) was added to PRP before the stimulation of ADP. tPA had no effect on platelet aggregation in alpha2-AP(+/+) mice, however platelet micro-aggregation in alpha2-AP(-/-) mice was markedly increased by the treatment with tPA. Moreover, the amount of released ATP from stimulated platelets was increased in alpha2-AP(-/-) mice treated with tPA. CONCLUSION:Lack of alpha2-AP increased platelet micro-aggregation, and plasmin plays an important role in the formation of platelet aggregation when alpha2-AP knockout mice are used. Consequently, the reduction of alpha2-AP could be a risk factor for the activation of platelets resulting in thrombus formation.

journal_name

J Thromb Thrombolysis

authors

Takei M,Matsuno H,Okada K,Ueshima S,Matsuo O,Kozawa O

doi

10.1023/a:1025096609558

subject

Has Abstract

pub_date

2002-12-01 00:00:00

pages

205-11

issue

3

eissn

0929-5305

issn

1573-742X

pii

5141741

journal_volume

14

pub_type

杂志文章
  • Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications.

    abstract::The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis. There is ample evidence from both laboratory and clinical studies to suggest that in addition to...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-018-1641-2

    authors: Gorog DA

    更新日期:2018-05-01 00:00:00

  • The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomes.

    abstract::Pylephlebitis, or suppurative thrombophlebitis of the portal vein, typically occurs in the context of an intraabdominal infection or abdominal sepsis. Antibiotics are the mainstay of treatment. The role of anticoagulation in the management of pylephlebitis is controversial, and data regarding its impact on outcomes is...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01949-z

    authors: Naymagon L,Tremblay D,Schiano T,Mascarenhas J

    更新日期:2020-02-01 00:00:00

  • Thromboembolic complications in inflammatory bowel disease.

    abstract::Patients with inflammatory bowel disease (IBD) have a 1.5-3.5-fold higher risk of thromboembolism when compared to the non-IBD population and the risk is much more prominent at the time of a flare. Arterial thromboembolism (ischemic stroke, focal white matter ischemia, cardiac ischemia, peripheral vascular disease and...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-014-1129-7

    authors: Kohoutova D,Moravkova P,Kruzliak P,Bures J

    更新日期:2015-05-01 00:00:00

  • Platelet glycoprotein Ibalpha gene polymorphism and massive or submassive pulmonary embolism.

    abstract:OBJECTIVE:The -5T/C polymorphism in the Kozak sequence of glycoprotein Ibalpha, a component of the platelet glycoprotein Ib-IX-V receptor complex, is associated with an increase in this receptor density on the surface of the platelet. This study was designed to investigate the effect of platelet glycoprotein Ibalpha Ko...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-008-0204-3

    authors: Soylu A,Tokaç M,Cora T,Düzenli MA,Acar H

    更新日期:2009-04-01 00:00:00

  • Molecular pathogenesis of plasminogen Hakodate: the second Japanese family case of severe type I plasminogen deficiency manifested late-onset multi-organic chronic pseudomembranous mucositis.

    abstract::A 64-year-old man first developed ligneous conjunctivitis at the age of 58 years after right pulmonary resection because of suspected cancer; otherwise, he had been healthy. Since then, he began to suffer from various forms of chronic pseudomembranous mucositis. Laboratory tests demonstrated that he had 7.8 % of plasm...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1375-y

    authors: Osaki T,Souri M,Song YS,Izumi N,Law R,Ichinose A

    更新日期:2016-08-01 00:00:00

  • Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?

    abstract::Patients with Coronavirus-associated disease-2019 (COVID-19) display alterations of the hemostatic system and the presence of a prothrombotic status frequently leading to vascular complications. However, the impact of COVID-19 on platelet activity, aggregation and agglutination still needs to be clarified. We measured...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02339-6

    authors: Ruberto F,Chistolini A,Curreli M,Frati G,Marullo AGM,Biondi-Zoccai G,Mancone M,Sciarretta S,Miraldi F,Alessandri F,Ceccarelli G,Barone F,Santoro C,Alvaro D,Pugliese F,Pulcinelli FM,Policlinico Umberto I COVID-19 Group.

    更新日期:2021-01-02 00:00:00

  • Circulating p53 and cytochrome c levels in acute myocardial infarction patients.

    abstract:BACKGROUND:Apoptosis causes myocardiocyte loss during and after myocardial infarction. Therapeutic approaches designed to arrest apoptosis would be a significant new development in the recovery of acute myocardial infarction (AMI). In order to examine apoptotic markers in the circulation, serum levels of p53 and cytoch...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-009-0328-0

    authors: Dincer Y,Himmetoglu S,Bozcali E,Vural VA,Akcay T

    更新日期:2010-01-01 00:00:00

  • Pharmacokinetics of rivaroxaban after bariatric surgery: a case report.

    abstract::Rivaroxaban is a direct factor Xa inhibitor, which is rapidly absorbed in the upper gastrointestinal (GI) tract. In large trials, it has been shown to be effective and safe in VTE treatment. However, in these trials patients with morbid obesity were not reported and it is unknown if the standard dosage of 20 mg rivaro...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-013-0891-2

    authors: Mahlmann A,Gehrisch S,Beyer-Westendorf J

    更新日期:2013-11-01 00:00:00

  • Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention.

    abstract::Point-of-care whole blood coagulation tests are critical in the management of patients who undergo percutaneous coronary intervention. The Hemochron and HemoTec devices have been traditionally used to measure the activated clotting time (ACT) in the cardiac catheterization laboratory. The heparin management test (HMT)...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1011908803939

    authors: Tsimikas S,Beyer R,Hassankhani A

    更新日期:2001-05-01 00:00:00

  • Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials.

    abstract::Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke. Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin may provide greater protection against subsequent stroke than monotherapy. Electronic databases were searched for randomized clinical trials (RCTs) compar...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,meta分析

    doi:10.1007/s11239-018-1786-z

    authors: Kheiri B,Osman M,Abdalla A,Haykal T,Swaid B,Ahmed S,Chahine A,Hassan M,Bachuwa G,Al Qasmi M,Bhatt DL

    更新日期:2019-02-01 00:00:00

  • Circulating lipid levels and risk of coronary artery disease in a large group of patients undergoing coronary angiography.

    abstract::A main underlying pathology of coronary artery disease is the deposition of cholesterol in the arteries supplying blood to the heart that leads to stenosis and myocardial infarction. We tested if dyslipidemia is a risk factor for coronary artery disease in the Lebanese population, and studied the role of the total cho...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s11239-014-1069-2

    authors: Platt DE,Ghassibe-Sabbagh M,Youhanna S,Hager J,Cazier JB,Kamatani Y,Salloum AK,Haber M,Romanos J,Doueihy B,Mouzaya F,Kibbani S,Sbeite H,Deeb ME,Chammas E,El Bayeh H,Khazen G,Gauguier D,Zalloua PA,Abchee AB,FGENTCA

    更新日期:2015-01-01 00:00:00

  • Platelet count trends and response to fondaparinux in a cohort of heparin-induced thrombocytopenia suspected patients after pulmonary endarterectomy.

    abstract::A definitive diagnosis of heparin-induced thrombocytopenia (HIT) is difficult to make, especially in patients undergoing cardiac surgery. In this retrospective cohort study, we assessed the platelet count trends and the response to fondaparinux in a population of patients of suspected HIT after pulmonary endarterectom...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02260-y

    authors: Li JF,Wu LJ,Wen GY,Zhou RR,Liu F,Wang W,Yang SQ,Gong JN,Miao R,Gu S,Liu Y,Yang YH

    更新日期:2020-09-07 00:00:00

  • Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.

    abstract:BACKGROUND:Venous thromboembolism (VTE) is a significant cause of mortality and morbidity in medical patients. Although thromboprophylaxis with enoxaparin reduces the risk of VTE in these patients, the optimal duration of therapy is not currently known. The EXCLAIM (EXtended CLinical prophylaxis in Acutely Ill Medical ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-006-7732-5

    authors: Hull RD,Schellong SM,Tapson VF,Monreal M,Samama MM,Turpie AG,Wildgoose P,Yusen RD

    更新日期:2006-08-01 00:00:00

  • Benefits versus risks of pharmacological prophylaxis to prevent symptomatic venous thromboembolism in unselected medical patients revisited. Meta-analysis of the medical literature.

    abstract::A significant proportion of the outcomes reported in trials assessing venous thromboembolism (VTE) prophylaxis in medical patients are related to asymptomatic events found on routine imaging studies. The implications of these events are controversial. Moreover, such trials did not always reflect the patient mix in tod...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-012-0730-x

    authors: Vardi M,Steinberg M,Haran M,Cohen S

    更新日期:2012-07-01 00:00:00

  • Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital.

    abstract::Warfarin is among the ten drugs most commonly involved in adverse drug reactions, has a narrow therapeutic index and complex dosage regimen, exhibits enormous variability dose-response and high risk drug-drug interactions. To analyze the profile of pharmacoepidemiological drug prescriptions for warfarin in patients ad...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-013-1030-9

    authors: Guidoni CM,Obreli-Neto PR,Pereira LR

    更新日期:2014-05-01 00:00:00

  • Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis.

    abstract::The Tissue Factor/Factor VIIa (TF/FVIIa) complex is an attractive target for pharmacological interruption of thrombin generation and hence blood coagulation, as this complex is the initiation point of the extrinsic pathway of coagulation. TF is a cell membrane-associated protein that interacts with soluble FVIIa to ac...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1023228827733

    authors: Szalony JA,Taite BB,Girard TJ,Nicholson NS,LaChance RM

    更新日期:2002-10-01 00:00:00

  • Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction.

    abstract:BACKGROUND:Sulfonylurea compounds may impair ischemic preconditioning and endogenous fibrinolysis. Increased mortality has been reported in diabetics receiving these drugs prior to admission for acute myocardial infarction when treated by direct angioplasty. Although thrombolytics are currently employed far more freque...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1012979622945

    authors: Halkin A,Roth A,Jonas M,Behar S

    更新日期:2001-10-01 00:00:00

  • Acquired factor V inhibitors: a systematic review.

    abstract::The occurrence of an inhibitor against coagulation factor V (FV) is a rare but challenging condition, which may span from asymptomatic laboratory abnormalities to potentially life-threatening bleeding. The onset of FV inhibitors has been associated most frequently in the past with the patients' exposure to topical bov...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-010-0529-6

    authors: Franchini M,Lippi G

    更新日期:2011-05-01 00:00:00

  • Antithrombin after cardiac surgery: implications on short and mid-term outcome.

    abstract:BACKGROUND:Antithrombin (AT) drop during cardiac surgery has been described. The causes and the effects of this phenomenon are not clear. The objective of the study is to evaluate the relationship of AT postoperative values on short and mid-term outcome after cardiac surgery. METHODS:Between January and June 2005, 405...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0191-9

    authors: Paparella D,Cappabianca G,Scrascia G,Fiore G,Paramythiotis A,Di Bari N,Liuzzi MP,Ibrahim MF,Fiore T,de Luca Tupputi Schinosa L

    更新日期:2009-01-01 00:00:00

  • Soluble P-selectin is not a surrogate marker for platelet P-selectin: evidence from a multicenter chest pain study group.

    abstract::It has been reported that platelet expression and plasma levels of soluble P-selectin are increased in patients with unstable coronary artery syndromes. However, the origin of soluble P-selectin remains unknown. We sought to determine whether platelet expression of P-selectin correlates with plasma levels in the popul...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1023/a:1018738502654

    authors: Gurbel PA,Kereiakes DJ,Serebruany VL

    更新日期:2000-08-01 00:00:00

  • Home management of INR in the public health system: feasibility of self-management of oral anticoagulation and long-term performance of individual POC devices in determining INR.

    abstract::The home prothrombin time/international normalized ratio (PT/INR) self-management could be convenient for patients, enhancing treatment compliance and improving the quality of the oral anticoagulation. However, patient self-management (PSM) of oral anticoagulation may not be feasible for up to half of the patients due...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1335-6

    authors: da Silva Saraiva S,Orsi FA,Santos MP,Machado T,Montalvão S,Costa-Lima C,de Paula EV,Colella MP,Annichino-Bizzacchi J

    更新日期:2016-07-01 00:00:00

  • Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.

    abstract::Direct oral anticoagulants are associated with rates of major bleeding which are not negligible, albeit lower than those associated with vitamin K antagonists. No specific reversal agent for factor Xa (FXa) direct inhibitors is currently available for clinical use. A modified activated human FXa decoy protein, andexan...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-018-1617-2

    authors: Sartori M,Cosmi B

    更新日期:2018-04-01 00:00:00

  • Effect of Poloxamer 188 on Collateral Blood Flow, Myocardial Infarct Size, and Left Ventricular Function in a Canine Model of Prolonged (3-Hour) Coronary Occlusion and Reperfusion.

    abstract::Poloxamer 188 is a surfactant with hemorheological, antithrombotic, and neutrophil-inhibitory properties. This agent has been demonstrated to reduce infarct size and to improve left ventricular function in animal models of myocardial infarction and reperfusion, and recently in a randomized trial of patients receiving ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/A:1008848026759

    authors: Kelly RF,Hursey TL,Patel RB,Parrillo JE,Schaer GL

    更新日期:1998-07-01 00:00:00

  • Impact of renal function on argatroban therapy during percutaneous coronary intervention.

    abstract::Argatroban, a hepatically metabolized direct thrombin inhibitor, is approved for anticoagulation in patients with or at risk of heparin-induced thrombocytopenia (HIT) undergoing percutaneous coronary intervention (PCI). We investigated the effect of renal function on argatroban therapy during PCI. From previous argatr...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-009-0357-8

    authors: Hursting MJ,Jang IK

    更新日期:2010-01-01 00:00:00

  • SARS-CoV-2 infection and thrombotic complications: a narrative review.

    abstract::The current, global situation regarding the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic and its potentially devastating clinical manifestations, i.e. coronavirus disease 2019 (COVID-19), took the world by storm, as millions of people have been infected worldwide and more than 1,600,000 patien...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-020-02374-3

    authors: Moschonas IC,Tselepis AD

    更新日期:2021-01-15 00:00:00

  • Prothrombotic gene polymorphisms and plasma factors in young North Indian survivors of acute myocardial infarction.

    abstract::The aim of this study was to evaluate the association of prothrombotic gene polymorphisms [factor V Leiden (FVL) 1691GA, factor VII (FVII) 10976GA, FVII HVR4, platelet membrane glycoproteins GP1BA 1018CT, GP1BA VNTR, integrin ITGB3 1565TC, integrin ITGA2 807CT and methylenetetrahydrofolate reductase (MTHFR) 677C/T], p...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-012-0734-6

    authors: Dogra RK,Das R,Ahluwalia J,Kumar RM,Talwar KK

    更新日期:2012-08-01 00:00:00

  • Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor.

    abstract::Reticulated platelets (RP) are young, hyperactive platelets that are increased during situations of enhanced platelet turnover such as acute myocardial infarction (AMI). The dynamics of RP levels after AMI is not established. We aimed to characterize the levels of circulating RP over time in patients with AMI. Patient...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-014-1156-4

    authors: Eisen A,Lerman-Shivek H,Perl L,Rechavia E,Leshem-Lev D,Zemer-Wassercug N,Dadush O,Kazum S,Codner P,Kornowski R,Lev EI

    更新日期:2015-07-01 00:00:00

  • Outpatient Therapy of Deep Vein Thrombosis.

    abstract::The initial treatment of acute venous thrombosis using low-molecular-weight heparin (LMWH) in the outpatient setting has been shown to be feasible, effective, and safe for selected patients when compared with in-hospital treatment using continuous intravenous heparin. There will always be a significant population of p...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1013232803747

    authors: Pineo GF,Hull RD

    更新日期:1998-01-01 00:00:00

  • Differential inhibitory effect of fondaparinux on the procoagulant potential of intact monocytes and monocyte-derived microparticles.

    abstract::Monocytes and monocyte-derived microparticles (MMPs) play a major role in acute coronary syndrome (ASC). Activated monocytes (ac-M) and MMPs support thrombin generation via tissue factor (TF). The aim of this study was to evaluate the inhibitory effect of fondaparinux, a selective Xa inhibitor, on thrombin generation ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-010-0490-4

    authors: Ben-Hadj-Khalifa-Kechiche S,Hezard N,Poitevin S,Remy MG,Florent B,Mahjoub T,Nguyen P

    更新日期:2010-11-01 00:00:00

  • Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.

    abstract:UNLABELLED:Platelet P-selectin and activated glycoprotein IIb-IIIa (GPIIb-IIIa) are markers of platelet activation and mediates platelet aggregation. Prasugrel (Pras) 5 mg may be used in very elderly (VE) acute coronary syndrome (ACS) patients undergoing PCI, but its effect on platelet P-selectin and activated GPIIb-II...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-016-1372-1

    authors: Wagner H,Lood C,Borna C,Gidlöf O,Truedsson L,Brown P,Zhou C,Winters K,Jakubowski JA,Erlinge D

    更新日期:2016-10-01 00:00:00